Selective Bruton's tyrosine kinase inhibitor and use thereof

1. A compound, having a structure of Formula II or Formula II′:

or their optical isomers, or pharmaceutically acceptable salts or solvates;

where each Rg is independently H, halogen, —CF 2 H, —CF 3 , —CN, C1-C3 alkyl, or C1-C3 alkoxy;

n is selected from 0, 1 and 2;

Rd is selected from

Re is selected from H, CH 3 , C2-C6 alkyl, C1-C6 azaalkyl, and C1-C6 oxaalkyl, wherein CH 3 , C2-C6 alkyl, C1-C6 azaalkyl and C1-C6 oxaalkyl are further substituted with amino, hydroxyl, and C1-C3 alkyl;

Y 1 , Y 2 , Y 3 and Y 4 are independently selected from C(Rf) and N, and at least one of Y 1 , Y 2 , Y 3 and Y 4 is N, wherein Rf is selected from H, halogen, C1-C3 alkyl, —CF 3 , and —CF 2 H.

2. A compound according to claim 1 , having a structure of Formula III or Formula III′ or Formula III″:

and their optical isomers, or pharmaceutically acceptable salts or solvates;

where each Rg is independently H, halogen, —CF 2 H, —CF 3 , C1-C3 alkyl, or C1-C3 alkoxy;

n is selected from 0, 1 and 2;

Rd is selected from

Re is selected from H, CH 3 , C2-C6 alkyl, C1-C6 azaalkyl, and C1-C6 oxaalkyl, wherein CH 3 , C2-C6 alkyl, C1-C6 azaalkyl and C1-C6 oxaalkyl are further substituted with amino, hydroxyl, and C1-C3 alkyl;

Y 1 and Y 2 are independently selected from C(Rf) and N, wherein Rf is selected from H, halogen, C1-C3 alkyl, —CF 3 , and —CF 2 H.

3. A compound according to claim 2 , having a structure of Formula IV or Formula IV′ or Formula IV″:

and their optical isomers, or pharmaceutically acceptable salts or solvates;

where each Rg is independently H, halogen, —CF 2 H, —CF 3 , C1-C3 alkyl, or C1-C3 alkoxy;

n is selected from 0, 1 and 2;

Rd is selected from

Re is selected from H, CH 3 , C2-C6 alkyl, C1-C6 azaalkyl, and C1-C6 oxaalkyl, wherein CH 3 , C2-C6 alkyl, C1-C6 azaalkyl and C1-C6 oxaalkyl are further substituted with amino, hydroxyl, and C1-C3 alkyl;

Rh is independently selected from H, halogen, C1-C3 alkyl, —CF 3 , and —CF 2 H.

4. A compound according to claim 3 , having a structure of Formula V or Formula V′ or Formula V″:

and their optical isomers, or pharmaceutically acceptable salts or solvates;

where each Rg is independently H, halogen, —CF 2 H, —CF 3 , C1-C3 alkyl, or C1-C3 alkoxy;

n is selected from 0, 1 and 2;

Re is selected from H, CH 3 , C2-C6 alkyl, C1-C6 azaalkyl, and C1-C6 oxaalkyl, wherein CH 3 , C2-C6 alkyl, C1-C6 azaalkyl and C1-C6 oxaalkyl are further substituted with amino, hydroxyl, and C1-C3 alkyl;

Rh is selected from H, halogen, C1-C3 alkyl, —CF 3 , and —CF 2 H.

5. A compound according to claim 4 , having a structure of Formula VI or Formula VI′ or Formula VI″:

and their optical isomers, or pharmaceutically acceptable salts or solvates;

where each Rg is independently H, halogen, —CF 2 H, —CF 3 , C1-C3 alkyl, or C1-C3 alkoxy;

n is selected from 0, 1 and 2;

Rh is independently selected from H, halogen, C1-C3 alkyl, —CF 3 , and —CF 2 H.

6. A compound according to claim 5 , having a structure of Formula VI-a or Formula VI-a′ or Formula VI-a″:

and their optical isomers, or pharmaceutically acceptable salts or solvates;

where each Rg is independently H, halogen, —CF 2 H, —CF 3 , C1-C3 alkyl, or C1-C3 alkoxy;

Rh is independently selected from H, halogen, C1-C3 alkyl, —CF 3 , and —CF 2 H.

7. A compound according to claim 6 , having a structure of Formula VI-a-1 or Formula VI-a-2′:

where each Rg is independently H, halogen, —CF 2 H, —CF 3 , C1-C3 alkyl, or C1-C3 alkoxy;

Ri is independently selected from H, halogen, C1-C3 alkyl, —CF 3 , and —CF 2 H.

8. A compound according to claim 3 , having a structure of Formula VII or Formula VII′ or Formula VII″:

and their optical isomers, or pharmaceutically acceptable salts or solvates;

where each Rg is independently H, halogen, —CF 2 H, —CF 3 , C1-C3 alkyl, or C1-C3 alkoxy;

n is selected from 0, 1 and 2;

Re is selected from H, CH 3 , C2-C6 alkyl, C1-C6 azaalkyl, and C1-C6 oxaalkyl, wherein CH 3 , C2-C6 alkyl, C1-C6 azaalkyl and C1-C6 oxaalkyl may be further substituted with amino, hydroxyl, and C1-C3 alkyl;

Rh is independently selected from H, halogen, C1-C3 alkyl, —CF 3 , and —CF 2 H.

9. A compound according to claim 8 , having a structure of Formula VIII or Formula VIII′ or Formula VIII″:

and their optical isomers, or pharmaceutically acceptable salts or solvates;

where each Rg is independently H, halogen, —CF 2 H, —CF 3 , C1-C3 alkyl, or C1-C3 alkoxy;

n is selected from 0, 1 and 2;

Rh is independently selected from H, halogen, C1-C3 alkyl, —CF 3 , and —CF 2 H.

10. A compound according to claim 1 , having a structure of one of the following formulas:

and their optical isomers, or pharmaceutically acceptable salts or solvates.

11. A compound of claim 1 , wherein the azaalkyl refers to that one or more carbon atoms of C1-C6 alkyl are substituted by nitrogen atoms; the oxaalkyl refers to that one or more carbon atoms of C1-C6 alkyl are substituted by oxygen atoms.

12. A pharmaceutical composition, comprising one or more of the compounds of claim 1 .

13. A pharmaceutical preparation, comprising at least one active component, wherein the active component(s) is/are one or more of the compounds of claim 1 .

14. A pharmaceutical composition, comprising one or more of the compounds of claim 10 .

15. A method of inhibiting Bruton's tyrosine kinase activity, comprising the step of administering a subject the compound of claim 1 .

16. A method of treating B-cell proliferation related diseases, selected from the group consisting of diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, B cell lymphocytic leukemia, Precursor B-cell lymphoblastic leukemia, lymphatic lymphoma/Waldenström macroglobulinemia, splenic marginal lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, lymph node marginal zone B cell lymphoma, mantle cell lymphoma, mediastinum (thymus) large B-cell lymphoma, intravascular large B-cell lymphoma, primary exudative lymphoma, Burkitt lymphoma/leukemia and lymphomatoid granulomatous disease, comprising the step of administering a subject the compound of claim 1 alone or in combination with other drugs.

17. A method of treating autoimmune diseases, selected from the group consisting of inflammatory bowel disease, arthritis, lupus, rheumatoidarthritis, psoriatic arthritis, osteoarthritis, Still's disease, juvenile arthritis, diabetes, myasthenia gravis, Hashimoto's thyroiditis, Ord's thyroiditis, Graves'disease, Sjögren's syndrome, multiple sclerosis, Guillain-Barré syndrome, acute disseminated encephalomyelitis, Addison's disease, visual ocular palsymyoclonusSyndrome, mandatory spondylitis, antiphospholipid antibody syndrome, aplastic anemia, autoimmune hepatitis, coeliac disease, Goodpasture's syndrome, idiopathic thrombocytopenic purpura, optic neuritis, scleroderma, primary biliary cirrhosis, Reiter's syndrome, Takayasu's arteritis, temporalarteritis, warm autoimmune hemolytic anemia, Wegener's granulomatosis, psoriasis, generalized hairremoval, Behçet's disease, chronic fatigue, familial dysautonomia, endometriosis, interstitial cystitis, neuromuscular rigidity, scleroderma or vulvar pain, and chronic graft-versus-host disease, comprising the step of administering a subject the compound of claim 1 alone or in combination with other drugs.

18. A method of treating rheumatoid arthritis and lupus erythematosus, comprising the step of administering a subject the compound of claim 1 alone or in combination with other drugs.

19. A method of inhibiting Bruton's tyrosine kinase activity, comprising the step of administering a subject the compound of claim 10 .